Scott & Selber Inc. cut its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 3.6% in the second quarter, Holdings Channel.com reports. The institutional investor owned 1,735 shares of the medical instruments supplier’s stock after selling 65 shares during the quarter. Scott & Selber Inc.’s holdings in Becton Dickinson and were worth $437,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Duality Advisers LP grew its position in shares of Becton Dickinson and by 12.7% during the 1st quarter. Duality Advisers LP now owns 17,480 shares of the medical instruments supplier’s stock valued at $4,365,000 after acquiring an additional 1,970 shares during the period. Meridian Wealth Advisors LLC boosted its holdings in Becton Dickinson and by 2.7% in the 1st quarter. Meridian Wealth Advisors LLC now owns 3,787 shares of the medical instruments supplier’s stock worth $946,000 after buying an additional 99 shares during the period. Pratt Collard Advisory Partners LLC boosted its holdings in Becton Dickinson and by 5.1% in the 1st quarter. Pratt Collard Advisory Partners LLC now owns 2,078 shares of the medical instruments supplier’s stock worth $519,000 after buying an additional 100 shares during the period. Investec Asset Management North America Inc. boosted its holdings in Becton Dickinson and by 5.1% in the 1st quarter. Investec Asset Management North America Inc. now owns 11,123 shares of the medical instruments supplier’s stock worth $2,778,000 after buying an additional 543 shares during the period. Finally, Black Diamond Financial LLC bought a new position in Becton Dickinson and in the 2nd quarter worth $562,000. Institutional investors and hedge funds own 85.07% of the company’s stock.

Shares of BDX traded up $4.92 during midday trading on Tuesday, hitting $254.08. 50,800 shares of the company traded hands, compared to its average volume of 1,066,327. The firm has a 50 day simple moving average of $251.93. Becton Dickinson and Co has a 52 week low of $208.62 and a 52 week high of $265.87. The stock has a market cap of $68.66 billion, a PE ratio of 23.07, a price-to-earnings-growth ratio of 1.85 and a beta of 1.11. The company has a debt-to-equity ratio of 0.84, a quick ratio of 0.67 and a current ratio of 1.09.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 EPS for the quarter, beating the consensus estimate of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The business had revenue of $4.35 billion during the quarter, compared to the consensus estimate of $4.37 billion. During the same quarter in the prior year, the firm earned $2.91 EPS. The business’s revenue was up 1.7% on a year-over-year basis. On average, equities analysts anticipate that Becton Dickinson and Co will post 11.68 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 1.21%. The ex-dividend date of this dividend is Friday, September 6th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

Several research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a report on Monday, May 20th. ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Morgan Stanley upped their target price on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 16th. Wells Fargo & Co dropped their target price on shares of Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating for the company in a report on Monday, May 13th. Finally, Barclays raised shares of Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 target price for the company in a report on Monday, May 13th. Five analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and presently has a consensus rating of “Buy” and an average price target of $264.27.

In other news, insider James C. Lim sold 1,929 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $252.01, for a total transaction of $486,127.29. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Samrat S. Khichi sold 16,085 shares of the company’s stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $234.68, for a total transaction of $3,774,827.80. Following the sale, the executive vice president now owns 12,608 shares in the company, valued at $2,958,845.44. The disclosure for this sale can be found here. Insiders have sold a total of 24,529 shares of company stock valued at $5,836,116 in the last three months. Insiders own 0.12% of the company’s stock.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: What is the return on assets (ROA) ratio?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.